Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Volitionrx (VNRX) Cash from Financing Activities (2019 - 2025)

Historic Cash from Financing Activities for Volitionrx (VNRX) over the last 9 years, with Q3 2025 value amounting to $1.6 million.

  • Volitionrx's Cash from Financing Activities fell 7144.65% to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.2 million, marking a year-over-year increase of 3047.08%. This contributed to the annual value of $8.7 million for FY2024, which is 7012.96% down from last year.
  • As of Q3 2025, Volitionrx's Cash from Financing Activities stood at $1.6 million, which was down 7144.65% from $5.7 million recorded in Q2 2025.
  • Volitionrx's 5-year Cash from Financing Activities high stood at $20.2 million for Q1 2021, and its period low was -$460198.0 during Q2 2022.
  • For the 5-year period, Volitionrx's Cash from Financing Activities averaged around $4.1 million, with its median value being $2.1 million (2021).
  • Examining YoY changes over the last 5 years, Volitionrx's Cash from Financing Activities showed a top increase of 1320322.56% in 2022 and a maximum decrease of 19181.39% in 2022.
  • Quarter analysis of 5 years shows Volitionrx's Cash from Financing Activities stood at $2.1 million in 2021, then plummeted by 55.85% to $925964.0 in 2022, then soared by 307.19% to $3.8 million in 2023, then crashed by 39.27% to $2.3 million in 2024, then tumbled by 30.13% to $1.6 million in 2025.
  • Its Cash from Financing Activities stands at $1.6 million for Q3 2025, versus $5.7 million for Q2 2025 and $3.7 million for Q1 2025.